Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: emerging role of tivantinib

References

• BirchmeierCBirchmeierWGherardiEVande WoudeGFMet, metastasis, motility and moreNat Rev Mol Cell Biol200341291592514685170
   PubMed Web of Science ®Google Scholar
• ComoglioPMGiordanoSTrusolinoLDrug development of MET inhibitors: targeting oncogene addiction and expedienceNat Rev Drug Discov20087650451618511928
   PubMed Web of Science ®Google Scholar
• GherardiEBirchmeierWBirchmeierCVande WoudeGTargeting MET in cancer: rationale and progressNat Rev Cancer20121228910322270953
   PubMed Web of Science ®Google Scholar
• TrusolinoLBertottiAComoglioPMMET signalling: principles and functions in development, organ regeneration and cancerNat Rev Mol Cell Biol2010111283484821102609
   PubMed Web of Science ®Google Scholar
• AndermarcherESuraniMAGherardiECo-expression of the HGF/SF and c-Met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesisDev Genet19961832542668631159
   PubMedGoogle Scholar
• BladtFRiethmacherDIsenmannSAguzziABirchmeierCEssential role for the c-Met receptor in the migration of myogenic precursor cells into the limb budNature199537665437687717651534
   PubMed Web of Science ®Google Scholar
• BussolinoFDi RenzoMFZicheMHepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growthJ Cell Biol199211936296411383237
   PubMed Web of Science ®Google Scholar
• StreitASternCDTheryCA role for HGF/SF in neural induction and its expression in Hensen’s node during gastrulationDevelopment199512138138247720585
   PubMed Web of Science ®Google Scholar
• TakayamaHLa RochelleWJAnverMBockmanDEMerlinoGScatter factor/hepatocyte growth factor as a regulator of skeletal muscle and neural crest developmentProc Natl Acad Sci U S A19969312586658718650184
   PubMed Web of Science ®Google Scholar
• MatsumotoKNakamuraTHepatocyte growth factor: renotropic role and potential therapeutics for renal diseasesKidney Int20015962023203811380804
   PubMed Web of Science ®Google Scholar
• MichalopoulosGKDeFrancesMCLiver regenerationScience1997276530960669082986
   PubMed Web of Science ®Google Scholar
• NakamuraTMizunoSMatsumotoKSawaYMatsudaHMyocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGFJ Clin Invest2000106121511151911120758
   PubMed Web of Science ®Google Scholar
• SchmidtCBladtFGoedeckeSScatter factor/hepatocyte growth factor is essential for liver developmentNature199537365166997027854452
   PubMed Web of Science ®Google Scholar
• LiuYYangJHepatocyte growth factor: new arsenal in the fights against renal fibrosis?Kidney Int200670223824016838037
   PubMed Web of Science ®Google Scholar
• UekiTKanedaYTsutsuiHHepatocyte growth factor gene therapy of liver cirrhosis in ratsNat Med1999522262309930873
   PubMed Web of Science ®Google Scholar
• WatanabeMEbinaMOrsonFMHepatocyte growth factor gene transfer to alveolar septa for effective suppression of lung fibrosisMol Ther2005121586715963921
   PubMed Web of Science ®Google Scholar
• FurgeKAZhangYWVande WoudeGFMet receptor tyrosine kinase: enhanced signaling through adapter proteinsOncogene200019495582558911114738
   PubMed Web of Science ®Google Scholar
• ZhangYWVande WoudeGFHGF/SF-met signaling in the control of branching morphogenesis and invasionJ Cell Biochem200388240841712520544
   PubMed Web of Science ®Google Scholar
• BirchmeierCGherardiEDevelopmental roles of HGF/SF and its receptor, the c-Met tyrosine kinaseTrends Cell Biol19988104044109789329
   PubMed Web of Science ®Google Scholar
• CiprianiNAAbidoyeOOVokesESalgiaRMET as a target for treatment of chest tumorsLung Cancer200963216917918672314
   PubMed Web of Science ®Google Scholar
• JiangWHiscoxSMatsumotoKNakamuraTHepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancerCrit Rev Oncol Hematol199929320924810226727
   PubMed Web of Science ®Google Scholar
• JiangWGHiscoxSEParrCAntagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cellsClin Cancer Res19995113695370310589789
   PubMed Web of Science ®Google Scholar
• FengYThiagarajanPSMaPCMET signaling: novel targeted inhibition and its clinical development in lung cancerJ Thorac Oncol20127245946722237263
   PubMed Web of Science ®Google Scholar
• BeanJBrennanCShihJYMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProc Natl Acad Sci U S A200710452209322093718093943
   PubMed Web of Science ®Google Scholar
• KatayamaRAoyamaAYamoriTCytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibitionCancer Res201373103087309623598276
   PubMed Web of Science ®Google Scholar
• SpigelDRBurrisHA3rdGrecoFARandomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancerJ Clin Oncol201129182582258921576636
   PubMed Web of Science ®Google Scholar
• ZhuMDoshiSGisleskogPOPopulation pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patientsJ Pharm Sci2014103132833624186235
   PubMed Web of Science ®Google Scholar
• SmithDCSmithMRSweeneyCCabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trialJ Clin Oncol201331441241923169517
   PubMed Web of Science ®Google Scholar
• OuSHKwakELSiwak-TappCActivity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplificationJ Thorac Oncol20116594294621623265
   PubMed Web of Science ®Google Scholar
• SantoroARimassaLBorbathITivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 studyLancet Oncol2013141556323182627
   PubMed Web of Science ®Google Scholar
• AdjeiAASchwartzBGarmeyEEarly clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancersOncologist201116678879921632449
   PubMed Web of Science ®Google Scholar
• MaPCTretiakovaMSMacKinnonACExpression and mutational analysis of MET in human solid cancersGenes Chromosomes Cancer200847121025103718709663
   PubMed Web of Science ®Google Scholar
• RikovaKGuoAZengQGlobal survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancerCell200713161190120318083107
   PubMed Web of Science ®Google Scholar
• MaPCJagadeeswaranRJagadeeshSFunctional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancerCancer Res20056541479148815735036
   PubMed Web of Science ®Google Scholar
• MaPCMaulikGChristensenJSalgiaRc-Met: structure, functions and potential for therapeutic inhibitionCancer Metastasis Rev200322430932512884908
   PubMed Web of Science ®Google Scholar
• Beau-FallerMRuppertAMVoegeliACMET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohortJ Thorac Oncol20083433133918379349
   PubMed Web of Science ®Google Scholar
• CappuzzoFJannePASkokanMMET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patientsAnn Oncol200920229830418836087
   PubMed Web of Science ®Google Scholar
• GoHJeonYKParkHJSungSWSeoJWChungDHHigh MET gene copy number leads to shorter survival in patients with non-small cell lung cancerJ Thorac Oncol20105330531320107422
   PubMed Web of Science ®Google Scholar
• KantetiRYalaSFergusonMKSalgiaRMET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significanceJ Environ Pathol Toxicol Oncol2009282899819817696
   PubMed Web of Science ®Google Scholar
• OnitsukaTUramotoHOnoKComprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor statusJ Thorac Oncol20105559159620150826
   PubMed Web of Science ®Google Scholar
• DziadziuszkoRWynesMWSinghSCorrelation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancerJ Thorac Oncol20127234034722237262
   PubMed Web of Science ®Google Scholar
• IchimuraEMaeshimaANakajimaTNakamuraTExpression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significanceJpn J Cancer Res19968710106310698957065
   PubMedGoogle Scholar
• TsaoMSLiuNChenJRDifferential expresssion of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancersLung Cancer19982011169699182
   PubMed Web of Science ®Google Scholar
• TsutaKKozuYMimaeTc-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomasJ Thorac Oncol20127233133922198430
   PubMed Web of Science ®Google Scholar
• LutterbachBZengQDavisLJLung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survivalCancer Res20076752081208817332337
   PubMed Web of Science ®Google Scholar
• GoetschLBroussasMFabre-LafaySAbstract 2448: h224G11, a humanized whole antibody targeting the c-Met receptor, induces c-Met down-regulation and triggers ADCC functionsCancer Research2010708(Suppl 1)2448
   Google Scholar
• PuriNKhramtsovAAhmedSA selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenograftsCancer Res20076783529353417440059
   PubMed Web of Science ®Google Scholar
• EathirajSPalmaRVolckovaEDiscovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197J Biol Chem201128623206662067621454604
   PubMed Web of Science ®Google Scholar
• MunshiNJeaySLiYARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activityMol Cancer Ther2010961544155320484018
   PubMed Web of Science ®Google Scholar
• UnderinerTLHerbertzTMiknyoczkiSJDiscovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidatesAnticancer Agents Med Chem201010172720015007
   PubMed Web of Science ®Google Scholar
• PanBSChanGKChenardMMK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptorCancer Res20107041524153320145145
   PubMed Web of Science ®Google Scholar
• GuXWangCYuYInhibition of HGF/C-MET pathway by ARQ 197: characterization of pharmacodynamic markers in vitro and in vivoPoster presented at the 2009 American Association for Cancer Research Annual MeetingApril 18–22, 2009Denver, CO, USA
   Google Scholar
• AndersonKLiCMoreauJARQ 197, a small molecule inhibitor of c-MET prevents bone metastasis in a humanized mouse model of breast cancerPoster B184 presented at the AACR-NCI -EORTC international conferenceOctober 22–26, 2007San Francisco, CA, USA
   Google Scholar
• LiYChenDZhouWBroad spectrum anti cancer activity of ARQ 197, a highly selective oral c-MET inhibitor in multiple xenograft modelsPoster 2216 presented at the 2007 American Association for Cancer Research Annual MeetingApril 14–18, 2007Los Angeles, CA, USA
   Google Scholar
• RosenLSenzerNNemunaitisJPhase I dose escalation study and signs of anti-metastatic activity of ARQ 197, a selective c-Met inhibitorPaper presented at the AACR-NCI-EORTC international conferenceOctober 22–26, 2007San Francisco, CA, USA
   Google Scholar
• MekhailTRichTRosenLFinal results: a dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumorsJ Clin Oncol200927Suppl 153548
   Web of Science ®Google Scholar
• GarciaARosenLCunninghamCPhase I study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 doseJ Clin Oncol200725Suppl 18352517687157
   PubMed Web of Science ®Google Scholar
• YapTAFrentzasSTunuriuNFinal results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incoporating dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) studies investiagting the antiangiogenic activity of selective c-Met inhibitionJ Clin Oncol200927153523
   Web of Science ®Google Scholar
• GoldmanJRosenLLauxIPhase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinibOral presentation A6.5 at 13th International Association for the Study of Lung Cancer World ConferenceJuly 31 to Aug 2009San Francisco, CA, USA
   Google Scholar
• LauxGJJustRBradyKPhase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-MET inhibitor ARQ 197 and erlotinibJ Clin Oncol200927153549
   Web of Science ®Google Scholar
• WagnerADemetriGDChoyEPreliminary results from a phase 2 study of ARQ 197 in patients with microphthalmia transcription factor family (MiT) associated tumorsOral presentation 39313 to Connective Tissue Oncology SocietyNovember 5–7, 2009Miami, FL, USA
   Google Scholar
• AdjeiAASosmanJADyGKA phase I dose escalation trial of the c-MET inhibitor ARQ 197 administered in combination with sorafenib in adult patients with advanced solid tumorsPoster 3024 presented at American Society of Clinical Oncology scientific meetingJune 4–8, 2010Chicago, IL, USA
   Google Scholar
• CamachoLChenCLKazakinJA phase 1b dose escalation trial evaluating ARQ 197 administered in combination with gemcitabine to patients with advanced solid tumorsPaper presented at American Society of Clinical Oncology scientific meetingJune 4–8, 2010Chicago, IL, USA
   Google Scholar
• ClinicalTrials.govARQ 197 in combination with chemotherapy in patients with metastatic colorectal cancer2010 Available from: http://clinicaltrials.gov/ct2/show/NCT01075048Accessed April 17, 2014
   Google Scholar
• GoldmanJWLauxIChaiFPhase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinibCancer2012118235903591122605616
   PubMed Web of Science ®Google Scholar
• SequistLVvon PawelJGarmeyEGRandomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancerJ Clin Oncol201129243307331521768463
   PubMed Web of Science ®Google Scholar
• ScagliottiGVNovelloSSchillerJHRationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancerClin Lung Cancer201213539139522440336
   PubMed Web of Science ®Google Scholar
• [No authors listed]Arqule and Daiichi Sankyo announce discontinuation of phase III MARQUEE clinical trial in non-small cell lung cancer2012 Available from: http://files.shareholder.com/downloads/ARQL/0x0x603004/d4d3b6d2-4ce1-467f-979b-43f4c2613e01/Accessed April 17, 2014
   Google Scholar
• INC-QAEDGAR online via COMTEX-ITEM 2. Management discussion and analysis of financial condition and results of operations52013 Available from: http://www.marketwatch.com/story/10-q-arqule-inc-2013-05-08Accessed April 16, 2014
   Google Scholar
• European Society for Medical OncologyESMO @ ECC 2013: a Phase III study of tivantinib plus erlotinib did not meet a primary endpoint in patients with locally-advanced or metastatic, non-squamous NSCLC2013 Available from: http://www.esmo.org/Oncology-News/A-Phase-III-Study-of-Tivantinib-Plus-Erlotinib-Did-Not-Meet-a-Primary-Endpoint-in-Patients-with-Locally-advanced-or-Metastatic-Non-squamous-NSCLCAccessed April 17, 2014
   Google Scholar
• ClinicalTrials.govA Phase 3, randomized, double-blinded, placebo-controlled study of ARQ 197 plus erlotinib versus placebo plus erlotinib (ATTENTION) Available from: http://clinicaltrials.gov/ct2/show/NCT01377376Accessed April 17, 2014
   Google Scholar
• [No authors listed]Kyowa Hakko Kirin announces temporary suspension of patient enrollment for Phase 3 clinical study of ARQ 197 (tivantinib) in combination with erlotinib in non-small-cell lung cancer patients http://www.kyowa-kirin.com/news_releases/2012/pdf/e20120830_01.pdfAccessed April 17, 2014
   Google Scholar
• [No authors listed]Kyowa Hakko Kirin announces discontinuation for phase 3 clinical study of ARQ 197 (Tivantinib) in combination with erlotinib in Non-small cell lung cancer patients Available from: http://www.kyowa-kirin.com/news_releases/2012/pdf/e20121030_01.pdfAccessed April 17, 2014
   Google Scholar
• ClinicalTrials.govA Phase 2 randomized open-label study of erlotinib plus tivantinib (ARQ 197) versus single agent chemotherapy in previously treated KRAS mutation positive subjects with locally advanced or metastatic non-small cell lung cancer Available from: http://clinicaltrials.gov/ct2/show/NCT01395758?term=nct01395758&rank=1Accessed April 17, 2014
   Google Scholar
• ClinicalTrials.govARQ 197 plus erlotinib in patient with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer Available from: http://clinicaltrials.gov/ct2/show/NCT01580735?term=Tivantinib+and+lung+cancer&rank=6Accessed April 17, 2014
   Google Scholar
• KatayamaRAoyamaAYamoriTCytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibitionCancer Res201373103087309623598276
   PubMed Web of Science ®Google Scholar